Manual práctico de Trombosis y Hemostasia de la SETH

— 1 1 0 — I I . PA T O LO G Í A D E L A H E M O ST A S I A and a therapeutic target in immune thrombocytopenia. Nat Commun 2015;17;6:7737. 7. Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogene- sis of immune thrombocytopenia.Autoimmun Rev 2017;16:620-32. 8. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investi- gation and management of primary immune thrombocytopenia. Blood 2010;115:168-86. 9. Sanz MÁ,Vicente GarcíaV, Fernández A, López MF, Grande C, Jarque I, et al. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia. Med Clin (Barc) 2012;138:261.e1-261. 10. Neunert C, LimW, Crowther M, Cohen A, Solberg L Jr, Crowther MA.The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207. 11. González-Porras JR, Escalante F, Pardal E, Sierra M, García-Frade LJ, Redondo S, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Hae- matol 2013;91(3):236-41. 12. González-López TJ, Pascual C, Álvarez-Román MT, Fernández- Fuertes F, Sánchez-González B, Caparrós I, et al. Successful discon- tinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.Am J Hematol 2015;90:E40-3. 13. González-Porras JR,Mingot-CastellanoME,AndradeMM,AlonsoR, Caparrós I, Arratibel MC, et al. Use of eltrombopag after romi- plostim in primary immune thrombocytopenia. Br J Haematol 2015;169:111-6. 14. Arnold DM, Curtis BR, Bakchoul T; Platelet Immunology Scien- tific Subcommittee of the International Society on Thrombosis and Hemostasis. Recommendations for standardization of la- boratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:676-8. 15. Vogelsang G, Kickler TS, Bell WR. Post-transfusion purpura: a re- port of five patients and a review of the pathogenesis and mana- gement. Am J Hematol 1986;21:259. 16. Winkelhorst D, Oepkes D, Lopriore E. Fetal and neonatal alloim- mune thrombocytopenia: evidence based antenatal and postnatal management strategies. Expert Rev Hematol 2017;10:729-37. 17. Bussel JB,Zacharoulis S,Kramer K,McFarland JG,Pauliny J,Kaplan C. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005;45:176. 18. Bastida Bermejo JM, Hernández-Rivas JM, González-Porras JR. Novel approaches for diagnosing inherited platelet disorders. MedClin (Barc) 2017;148:71-7. 19. Lowe GC, Lordkipanidzé M,Watson SP; UK GAPP study group. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost 2013;11:1663-8. 20. Bastida JM, Lozano ML, Benito R, Janusz K, Palma-BarquerosV, Del Rey M, et al. Introducing high-throughput sequencing into mains- tream of genetic diagnosis practice in inherited platelet disorders. Haematologica 2018;103;148-62.